生长抑素联合加贝酯对重症急性胰腺炎临床转归的影响

目的探讨生长抑素联合加贝酯对重症急性胰腺炎（SAP）临床转归的影响,为临床诊治重症急性胰腺炎提供参考。方法 2008年8月至2010年8月收治重症急性胰腺炎患者110例,按照随机数字方法分成两组,对照组（55例）予以加贝酯治疗,而治疗组（55例）给以生长抑素联合加贝酯治疗,分析比较两组患者的临床资料。结果两组患者治疗后腹痛缓解时间、白细胞恢复时间、血淀粉酶恢复时间、住院天数等临床指标均具有统计学,治疗组较对照组时间明显缩短（P〈0.05）;在并发症发生率、转为外科治疗率、死亡率方面,治疗组也较对照组明显降低（P〈0.05）;治疗组总有效率也较对照组明显高（P〈0.05）。结论生长抑素联合加贝酯治疗重症急性胰腺炎可以缩短病程,减少并发症及死亡率,具有良好的治疗效果,对SAP疾病的转归起着重要作用。

Effect of gabexate mesilate combined with somatostatin on clinical prognosis of severe acute pancreatitis

Objective To investigate the effect of gabexate mesilate combined with somatostatin on clinical prognosis of severe acute pancreatitis.Methods Totally 110 patients with severe acute pancreatitis（SAP） were enrolled and randomly divided into control group（n=55） and treatment group（n=55）.The patients in control group were given gabexate mesilate while those in treatment group were treated by gabexate mesilate combined with somatostain.The clinical data of the two groups were compared and analyzed after the treatment finished.Results Statistical differences were found in the recovery time of abdominal pain,WBC and serum amylase as well as hospitalization duration between the two groups,less time was required in treatment group compared with that in control group（P0.05）.Meanwhile the patients in treatment group had better results in complication incidences,surgical treatment rate,mortality rate and total effective rate（P0.05）.Conclusion The therapy of gabexate mesilate combining with somatostatin can shorten the course of disease,reduce complications and mortality rate.This therapy has good therapeutic effect and plays an important role in the prognosis of severe acute pancreatitis.